Sri Lanka’s Hemas Holdings reported a 12.8% decline in group net profit to Rs. 2.6 billion for the December 2025 quarter, compared to the same period last year. The downturn was attributed to high costs and the adverse effects of Cyclone Ditwah on the broader business ecosystem.
According to interim results filed with the stock exchange, sales for the December 2025 quarter grew by 5.3% to Rs. 35.0 billion compared to the previous year. While the group’s revenue from fast-moving consumer goods decreased, the healthcare business experienced increased revenue during the quarter.
The basic earnings per share for the quarter stood at Rs. 0.88. Hemas shares remained stable, closing at 34.50 rupees per share.
The company stated that although its manufacturing and service facilities did not suffer direct physical damage, the broader business ecosystems in disaster-hit areas were significantly disrupted. This disruption was due to damage to personal assets, commercial premises, inventory losses, and disruptions to public transportation and logistics infrastructure.
The impact was felt by employees, distributors, and retail partners, including pharmacies. “These factors led to temporary supply-chain and distribution disruptions during November and December, alongside a short-term deterioration in consumer sentiment,” said Ashish Chandra, Group Chief Executive Officer, in the interim report.
“As a result, demand softness was observed during the latter part of the third quarter, particularly within the Consumer Brands and Healthcare sectors. Demand has since stabilized, with encouraging recovery trends evident as we enter the fourth quarter (January-March 2026),” he added.
For the nine months ending December 2025, Hemas reported basic earnings per share of Rs. 1.97. Group sales increased by 9.4% to Rs. 95.8 billion, while net profit rose by 7.5% to Rs. 5.9 billion.
(Colombo/February 03/2026)
